IGFBP3 Antibody (Antigen Affinity Purified)

IGFBP3 Antibody ( Antigen Affinity Purified ) Datasheet

IGFBP3 Antibody Product Information

• Immunogen: Recombinant Human IGFBP3 Protein (Catalog#10430-H07H)
• Antibody Type: Rabbit Polyclonal Antibody (Antibody Purification Platform)
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: Produced in rabbits immunized with purified, recombinant Human IGFBP3 (rh IGFBP3; Catalog#10430-H07H; NP_000589.2; Gly 28-Lys 291). IGFBP3 specific IgG was purified by Human IGFBP3 affinity chromatography.

IGFBP3 Antibody Usage Guide

• Specificity: Human IGFBP3
• Western blot: This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human IGFBP3 in WB. Using a DAB detection system, the detection limit for Human IGFBP3 is approximately 0.5 ng/lane under non-reducing conditions and 2 ng/lane under reducing conditions.
• Direct ELISA: This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human IGFBP3. The detection limit for Human IGFBP3 is approximately 0.00245 ng/well.
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

IGFBP3 Antibody Background

Insulin-like growth factor-binding proteins (IGFBPs) prolong the half-life of the IGFs, control bioavailability, activity, and distribution of insulin-like growth factor (IGF) through high-affinity IGFBP/IGF complexes. Six high-affinity IGF-binding proteins (IGFBP-1 to -6) have been identified. Human IGFBP3 is a widely expressed protein containing an IGFBP domain at the N-terminus and a thyroglobulin type-I domain. IGFBP3 forms a ternary complex of about 140 ~150 kDa with IGF1 or IGF2 and a glycoprotein insulin-like growth factor acid-labile subunit (ALS), thus alter the interaction of IGFs with their cell surface receptors. IGFBP3 exerts either proapoptotic or growth stimulatory effects depending upon the cellular context. Studies have shown that IGFBP3 can leads to the induction of apoptosis dependent or independent of the IGF-IGF receptor axis, accordingly acts as a negative regulator of tumorigenesis and progressing in certain carcinomas. In addition, IGFBP3 also interacts with the Alzheimer's survival peptide humanin (HN), playing a role in neurological disease processes.

References

1. Cubbage ML. et al., 1990, J Biol Chem. 265: 12642-9.
2. Ikonen M. et al., 2003, Proc Natl Acad Sci. 100: 130428-47.
3. Kim HS. et al., 2004, Cancer Res. 64: 2229-37.
4. Hong J. et al., 2002, J Biol Chem. 277: 10488-97.